Prostate Cancer Prevention: Agent Development Strategies

  • Howard L. ParnesEmail author
  • Margaret G. House
  • Joseph A. Tangrea
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)


Despite advances in surgery, radiation, and medical therapy over the past decade and the widespread adoption of PSA screening, prostate cancer continues to be the second leading cause of cancer death in men in the United States. Invasive cancer is the end result of carcinogenesis, a chronic process occurring over many years driven by genetic and epigenetic alterations. The protracted nature of this transformation to the malignant phenotype provides an opportunity to intervene pharmacologically to prevent, reverse, or delay carcinogenesis, i.e. chemoprevention. Herein, we describe the unique features of cancer prevention, as opposed to cancer treatment, agent development clinical trials, and provide a summary of the ongoing research in this field being supported by the National Cancer Institute.


Prostate Cancer Prostate Specific Antigen Prostate Specific Antigen Level Prostate Specific Antigen Screening Elevated Prostate Specific Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Algotar AM, Stratton MS, Ahmann FR et al (2013) Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. Prostate 73(3):328–335Google Scholar
  2. Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–202Google Scholar
  3. Bostwick DG, Qian J (2001) Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 58:91–93PubMedCrossRefGoogle Scholar
  4. Carducci MA WJ, Heath E, et al (2007) A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: evaluation of drug-specific biomarker modulation. Suppl J Clin Oncol ASCO Annu Meet Proc 25:235sGoogle Scholar
  5. Carter HB, Kettermann A, Warlick C et al (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359–2364 (Discussion 64–65)Google Scholar
  6. Chan JM, Weinberg V, Magbanua MJ et al (2011) Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes Control 22:141–150PubMedCentralPubMedCrossRefGoogle Scholar
  7. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19PubMedCentralPubMedCrossRefGoogle Scholar
  8. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985–1992PubMedCrossRefGoogle Scholar
  9. Huang X, Chen S, Xu L et al (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65:3470–3478PubMedGoogle Scholar
  10. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRefGoogle Scholar
  11. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170PubMedCrossRefGoogle Scholar
  12. Klein EA, Thompson IM Jr, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 306:1549–1556PubMedCrossRefGoogle Scholar
  13. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131Google Scholar
  14. Kronz JD, Allan CH, Shaikh AA, Epstein JI (2001) Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 25:1079–1085PubMedCrossRefGoogle Scholar
  15. Kumar NB, Krischer JP, Allen K et al (2007) A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 59:163–168PubMedCentralPubMedCrossRefGoogle Scholar
  16. Kumar N (2011) Personal communicationGoogle Scholar
  17. Lippman SM, Hong WK (2002) Cancer prevention science and practice. Cancer Res 62:5119–5125PubMedGoogle Scholar
  18. Lippman SM, Klein EA, Goodman PJ et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51PubMedCentralPubMedCrossRefGoogle Scholar
  19. Marshall JR, Tangen CM, Sakr WA et al (2011) Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 4:1761–1769CrossRefGoogle Scholar
  20. Nguyen MM, Ahmann FR, Nagle RB et al (2012) Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 5:290–298CrossRefGoogle Scholar
  21. Ozten-Kandas N, Bosland MC (2011) Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants—in vivo evidence. J Carcinog 10:27PubMedCentralPubMedCrossRefGoogle Scholar
  22. Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R (2004) Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention Portfolio. J Urol 171:S68–74. Discussion S5Google Scholar
  23. Renan MJ (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139–146PubMedCrossRefGoogle Scholar
  24. Sabichi AL, Lee JJ, Taylor RJ et al (2006) Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a southwest oncology group study. Clin Cancer Res 12:2178–2184PubMedCrossRefGoogle Scholar
  25. Schulman CC, Zlotta AR, Denis L, Schroder FH, Sakr WA (2000) Prevention of prostate cancer. Scand J Urol Nephrol Suppl 205:50–61Google Scholar
  26. Simoneau AR, Gerner EW, Nagle R et al (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomark Prev 17:292–299Google Scholar
  27. Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL (2012) Active surveillance for prostate cancer: past, present and future. Curr Opin Oncol 24:243–250PubMedCrossRefGoogle Scholar
  28. Sporn MB, Suh N (2000) Chemoprevention of cancer. Carcinogenesis 21:525–530Google Scholar
  29. Sporn MB, Suh N (2002) Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2:537–543PubMedCrossRefGoogle Scholar
  30. Stratton MS, Algotar AM, Ranger-Moore J et al (2010) Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 3:1035–1043CrossRefGoogle Scholar
  31. Thompson IM, Ankerst DP, Chi C et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98:529–534Google Scholar
  32. Thompson IM, Goodman PJ, Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224PubMedCrossRefGoogle Scholar
  33. Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC (2012) A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology 80(484):e17–e22PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Howard L. Parnes
    • 1
    Email author
  • Margaret G. House
    • 2
  • Joseph A. Tangrea
    • 2
  1. 1.Division of Cancer Prevention, 9609 Medical Center DriveNational Cancer InstituteBethesdaUSA
  2. 2.Division of Cancer PreventionNational Cancer InstituteBethesdaUSA

Personalised recommendations